Difference between revisions of "Malignant solid neoplasm, BRAF-mutated"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "{| class="wikitable" style="width: 100%; text-align:center;" !Study !Evidence |-" to "{| class="wikitable" style="width: 100%; text-align:center;" !style="width: 50%"|Study !style="width: 50%"|Evidence |-")
m
Line 1: Line 1:
−
<!--'''Use of this site is subject to you reading and agreeing with the terms set forth in the [[HemOnc.org_-_A_Hematology_Oncology_Wiki:General_disclaimer|disclaimer]]. If this is your first time visiting, we suggest you read the [[tutorial]].'''-->
 
−
 
−
<!--Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are [[How_to_contribute|invited to contribute to the site]].-->
 
−
 
 
{| class="wikitable" style="float:right; margin-right: 5px;"
 
{| class="wikitable" style="float:right; margin-right: 5px;"
 
|-
 
|-

Revision as of 03:19, 27 November 2018

2 regimens on this page
2 variants on this page


Note: this is a new type of page for HemOnc.org, as most other regimen pages are tissue-specific. We will collect published information from basket trials on these pages, as well as regimens that are FDA approved.

All lines of therapy

Dabrafenib & Trametinib

back to top

Regimen

Study Evidence
Subbiah et al. 2017 (BRF117019) Phase II

Note: only partial results have been published to date.

Chemotherapy

Continued indefinitely

References

  1. BRF117019: Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, Soria JC, Wen PY, Zielinski C, Cabanillas ME, Urbanowitz G, Mookerjee B, Wang D, Rangwala F, Keam B. Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer. J Clin Oncol. 2018 Jan 1;36(1):7-13. Epub 2017 Oct 26. link to original article contains verified protocol link to PMC article PubMed

Vemurafenib monotherapy

Regimen

Study Evidence
Hyman et al. 2015 (VE-BASKET) Phase II
Hainsworth et al. 2018 (MyPathway) Phase IIa

Eligibility criteria

  • VE-BASKET: BRAF p.V600 mutations
  • MyPathway: BRAF p.V600E mutation without coexisting KRAS mutations, or other BRAF mutations

Chemotherapy

Continued indefinitely

References

  1. VE-BASKET: Hyman DM, Puzanov I, Subbiah V, Faris JE, Chau I, Blay JY, Wolf J, Raje NS, Diamond EL, Hollebecque A, Gervais R, Elez-Fernandez ME, Italiano A, Hofheinz RD, Hidalgo M, Chan E, Schuler M, Lasserre SF, Makrutzki M, Sirzen F, Veronese ML, Tabernero J, Baselga J. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med. 2015 Aug 20;373(8):726-736. link to original article contains protocol link to PMC article PubMed
  2. MyPathway: Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, Burris H, Bose R, Yoo B, Stein A, Beattie M, Kurzrock R. Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open-label, phase IIa multiple basket study. J Clin Oncol. 2018 Feb 20;36(6):536-542. Epub 2018 Jan 10. link to original article contains verified protocol PubMed
Retrieved from "https://hemonc.org/w/index.php?title=Malignant_solid_neoplasm,_BRAF-mutated&oldid=32862"